ReviewFrontiers in immunology2026
Isolated orofacial dystonia and facial pain as the inaugural manifestation of anti-NMDAR encephalitis: a case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis typically presents with psychiatric symptoms, seizures, and cognitive dysfunction. Movement disorders, when present, usually coexist with these features. We report a rare case of anti-NMDAR encephalitis in a 30-year-old female who presented with isolated left temporomandibular joint (TMJ) dystonia, jaw tremor, and facial pain as the sole manifestations for seven months, without clinically significant psychiatric, cognitive, or seizure symptoms. The patient was repeatedly misdiagnosed with TMJ disorder and muscular dysfunction before anti-NMDAR IgG antibodies were detected by cell-based assay (CBA) in serum (1:32) and cerebrospinal fluid (CSF, 1:1). First-line immunotherapy with intravenous immunoglobulin (IVIG) achieved remission. However, she relapsed five months later following COVID-19 infection, with antibody titers rising to 1:100 in both serum and CSF. High-dose corticosteroid pulse therapy and maintenance mycophenolate mofetil were administered, achieving sustained clinical improvement over four years of follow-up, although mild residual focal dystonia persisted. Whole-exome sequencing and hereditary ataxia screening excluded genetic causes. This case broadens the clinical spectrum of anti-NMDAR encephalitis and underscores the importance of early antibody testing in young patients with treatment-refractory orofacial movement disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.